Corbus Pharmaceuticals
Committed to leveraging expertise in immunology to fulfill purpose of developing innovative new medicines
50 employees · est. 2014 · Norwood, United States
Corbus Pharmaceuticals is the older company (2015 vs 2014).
Side-by-Side Comparison
| Metric | Abcuro, Inc | Corbus Pharmaceuticals |
|---|---|---|
| Founded | ||
| Founded | 2015 | 2014 older |
| Headquarters | ||
| Headquarters | Not tracked yet | Norwood, United States |
| Employees | ||
| Employees | 43 | 50 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series B | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $214.85M | $341.45M |
| Funding Rounds | ||
| Funding Rounds | 5 | 12 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Immunotherapy, Autoimmune Diseases, Cancer Treatments, Clinical Stage, Anti-KLRG1 Antibody, Orphan Drug Designation, Tumor Microenvironment, Bioinformatics, Transcriptome Analysis, Immune-modulatory Bio-therapeutics, Target Validation, Clinical Insights, Cytotoxic T Cells, NK Cells | Precision Oncology, Cancer Immunotherapy, Antibody Drug Conjugate, TGFβ Inhibition, Endocannabinoid System, CB2 Agonist, Inflammatory Diseases, Fibrotic Diseases, Lenabasum, Fibrosis Resolution, Systemic Sclerosis, Cystic Fibrosis, Dermatomyositis, NASH, Phase 3 Clinical-stage Pharmaceutical Company |
| Website | ||
| Website | abcuro.com | corbuspharma.com |
About Abcuro, Inc
Abcuro, Inc is a clinical stage biotechnology company founded in 2015 that focuses on developing immunotherapies for autoimmune diseases and cancer. The company is known for its flagship products ABC008 and ABC015, both of which target cytotoxic T and NK cells expressing the inhibitory immune checkp...
About Corbus Pharmaceuticals
Corbus Pharmaceuticals is a precision oncology startup committed to leveraging expertise in immunology to develop innovative new medicines. The company's internal development pipeline includes CRB-701, a next-generation antibody drug conjugate (ADC) targeting the expression of Nectin 4 on cancer cel...
We will tell you when either one moves
BounceWatch watches Abcuro, Inc and Corbus Pharmaceuticals for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Abcuro, Inc and Corbus Pharmaceuticals — by email.
Frequently Asked Questions
Compare Abcuro, Inc with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Abcuro, Inc on 11 Sep 2024, and Corbus Pharmaceuticals on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.